Abstract
Background: Inorganic nanoparticles (NPs) including those derived from metals (e.g., gold, silver), semiconductors (e.g., quantum dots), carbon dots, carbon nanotubes, or oxides (e.g., iron oxide), have been deeply investigated recently for diagnostic and therapeutic purposes in oncology. Compared to organic nanomaterials, inorganic NPs have several advantages and unique characteristics for better imaging and drug delivery. Still, only a limited number of inorganic NPs are translated into clinical practice.
Method: In this review, we discuss the progression of inorganic NPs for cancer therapy and imaging, focusing our attention on opportunities, limitations and challenges for the main constituting nanomaterials, including metallic and magnetic NPs. In particular, the pre-clinical and clinical trials from the bench toward the clinic are here investigated.
Results: Over the last few decades, the development of wide range of NPs with the ability to tune size, composition and functionality, has provided an excellent resource for nanomedicine. Inorganic NPs provide a great opportunity as drug carriers, due to the easy modification of targeting molecules, the control of drug release by different stimuli, and the effective delivery to target sites, thus resulting in having an improved therapeutic efficacy and in reducing side effects. Inorganic NPs are investigated in preclinical and clinical studies for the detection, diagnosis and treatment of many diseases. The stability of inorganic NPs offers a potential advantage over the traditional delivery methods. Inorganic NPs could enhance and improve current imaging and diagnostic techniques, such as MRI or PET. Even though, they have not yet been approved for drug delivery applications, their ability to respond to external stimuli is now widely investigated in clinic.
Conclusion: The successful translation of inorganic NPs to the clinic requires the development of a simple, safe, cost-effective, ecofriendly mode of synthesis, and a better understanding of the safety mechanisms, biodistribution and the pharmacokinetics of NPs. However, more attention should be given to concerns on long-term toxicity, carcinogenesis, immunogenicity, inflammation and tissue damage. Although, some inorganic NPs, which were apparently promising in the preclinical phase, were found not to be successful when translated to the clinic, several encouraging NPs are currently being developed for treatment and cancer care and for a wide variety of other diseases.
Keywords: Cancer therapy, clinical trials, diagnostic, inorganic nanoparticles, magnetic nanoparticles, metallic nanoparticles, nanotechnology, theranostics.
Current Medicinal Chemistry
Title:Inorganic Nanoparticles for Cancer Therapy: A Transition from Lab to Clinic
Volume: 25 Issue: 34
Author(s): Samer Bayda, Mohamad Hadla, Stefano Palazzolo, Pietro Riello, Giuseppe Corona, Giuseppe Toffoli and Flavio Rizzolio*
Affiliation:
- Experimental and Clinical Pharmacology, Department of Translational Research, National Cancer Institute and Center for Molecular Biomedicine - CRO, Aviano,Italy
Keywords: Cancer therapy, clinical trials, diagnostic, inorganic nanoparticles, magnetic nanoparticles, metallic nanoparticles, nanotechnology, theranostics.
Abstract: Background: Inorganic nanoparticles (NPs) including those derived from metals (e.g., gold, silver), semiconductors (e.g., quantum dots), carbon dots, carbon nanotubes, or oxides (e.g., iron oxide), have been deeply investigated recently for diagnostic and therapeutic purposes in oncology. Compared to organic nanomaterials, inorganic NPs have several advantages and unique characteristics for better imaging and drug delivery. Still, only a limited number of inorganic NPs are translated into clinical practice.
Method: In this review, we discuss the progression of inorganic NPs for cancer therapy and imaging, focusing our attention on opportunities, limitations and challenges for the main constituting nanomaterials, including metallic and magnetic NPs. In particular, the pre-clinical and clinical trials from the bench toward the clinic are here investigated.
Results: Over the last few decades, the development of wide range of NPs with the ability to tune size, composition and functionality, has provided an excellent resource for nanomedicine. Inorganic NPs provide a great opportunity as drug carriers, due to the easy modification of targeting molecules, the control of drug release by different stimuli, and the effective delivery to target sites, thus resulting in having an improved therapeutic efficacy and in reducing side effects. Inorganic NPs are investigated in preclinical and clinical studies for the detection, diagnosis and treatment of many diseases. The stability of inorganic NPs offers a potential advantage over the traditional delivery methods. Inorganic NPs could enhance and improve current imaging and diagnostic techniques, such as MRI or PET. Even though, they have not yet been approved for drug delivery applications, their ability to respond to external stimuli is now widely investigated in clinic.
Conclusion: The successful translation of inorganic NPs to the clinic requires the development of a simple, safe, cost-effective, ecofriendly mode of synthesis, and a better understanding of the safety mechanisms, biodistribution and the pharmacokinetics of NPs. However, more attention should be given to concerns on long-term toxicity, carcinogenesis, immunogenicity, inflammation and tissue damage. Although, some inorganic NPs, which were apparently promising in the preclinical phase, were found not to be successful when translated to the clinic, several encouraging NPs are currently being developed for treatment and cancer care and for a wide variety of other diseases.
Export Options
About this article
Cite this article as:
Bayda Samer, Hadla Mohamad, Palazzolo Stefano, Riello Pietro, Corona Giuseppe, Toffoli Giuseppe and Rizzolio Flavio*, Inorganic Nanoparticles for Cancer Therapy: A Transition from Lab to Clinic, Current Medicinal Chemistry 2018; 25 (34) . https://dx.doi.org/10.2174/0929867325666171229141156
DOI https://dx.doi.org/10.2174/0929867325666171229141156 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Interactions Between Probiotic Dairy Propionibacteria and the Intestinal Epithelium
Current Immunology Reviews (Discontinued) Role of α -Crystallin B in Regulation of Stress Induced Cardiomyocyte Apoptosis
Cardiovascular & Hematological Agents in Medicinal Chemistry Design, Synthesis, and Biological Evaluation of Novel C5-Modified Pyrimidine Ribofuranonucleosides as Potential Antitumor or/and Antiviral Agents
Medicinal Chemistry Meet Our Editorial Board Member
Recent Patents on Anti-Cancer Drug Discovery Perspective on Nanoparticle Technology for Biomedical Use
Current Pharmaceutical Design Can Breast Cancer Stem Cells Evade the Immune System?
Current Medicinal Chemistry Epigenetics in Vascular Disease – Therapeutic Potential of New Agents
Current Vascular Pharmacology Non-Pharmacologic Strategies in Hematopoietic Stem Cell Transplantation
Current Pharmaceutical Design Genetic and Molecular Approaches to the Immunopathogenesis of Multiple Sclerosis: An Update
Current Molecular Medicine Medicinal Purposes: Bioactive Metabolites from Marine-derived Organisms
Mini-Reviews in Medicinal Chemistry Choline Kinase Active Site Provides Features for Designing Versatile Inhibitors
Current Topics in Medicinal Chemistry Patent Selections:
Recent Patents on Regenerative Medicine Placebos Used in Clinical Trials for Chinese Herbal Medicine
Recent Patents on Inflammation & Allergy Drug Discovery Editorial [Hot topic: Hepatocyte Growth Factor and cMET, New Development in Cancer Therapies (Guest Editors: T.A. Martin and W.G. Jiang)]
Anti-Cancer Agents in Medicinal Chemistry An Update on “Selenium Containing Compounds from Poison to Drug Candidates: A Review on the GPx-like Activity”
Current Chemical Biology Peripartum Cardiomyopathy: Current State of Knowledge, New Developments and Future Directions
Current Cardiology Reviews Synthesis, Characterization and Cholinesterase Inhibition Studies of New Arylidene Aminothiazolylethanone Derivatives
Medicinal Chemistry MicroRNAs (miRNAs) in Colorectal Cancer: From Aberrant Expression Towards Therapy
Current Pharmaceutical Design In the Crosshairs: NF-κB Targets the JNK Signaling Cascade
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Dysfunction of Mitochondrial ATP Production As a Target for Personalized Cancer Therapy
Current Pharmacogenomics and Personalized Medicine